Asish K. Ghosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Asish K. Ghosh has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Neil E. Kay
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
22 shared publications - Sutapa Sinha
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA
21 shared publications - Chao Xu
Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, USA
20 shared publications - Hasan Mahmud
Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
20 shared publications - Jennifer Holter Chakrabarty
Stephenson Cancer Center, University of Oklahoma
20 shared publications - Mamta Gupta
Department of Biochemistry and Molecular Medicine, George Washington University’s Cancer Center (GWCC), Washington, DC 20037, USA
20 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Leukemia
- p. 1-17
Aberrant expression of MERTK activates BCR via CD79a in CLL cells: alternative therapeutic strategy for relapsed/refractory CLL
Although therapies targeting BTK of BCR-signal are changing the landscape of CLL management, these agents are not curative and resistance can develop. Thus, we searched for other druggable target(s) regulating leukemic B-cell survival for developing alternative therapies. We detected MERTK, a member of the TAM (Tyro3, AXL, MERTK) family receptor tyrosine kinases (RTKs), is aberrantly expressed and constitutively active in CLL cells from ~65% CLL patients (n = 100). Ligation of Gas6, a common ligand for TAM-RTKs, preferentially activated MERTK resulting in activation of NF-κB/AKT/Erk1/2 and BTK in CLL cells. Partial depletion of MERTK in CLL cells reduced P-Erk1/2, P-NF-κB, P-AKT, and P-BTK levels, suggesting that MERTK may crosstalk with BCR-signal. Indeed, MERTK activated BTK by forming a signalosome with CD79a/LYN in CLL cells. Interestingly, stimulation of BCR-signals in CLL cells activated MERTK via CD79a, suggesting that MERTK/BCR-signals are functionally connected. Importantly, targeting MERTK using a high-affinity, pharmacologic inhibitor UNC-2025 induced apoptosis in CLL cells and reduced leukemic burden in vivo. More significantly, ibrutinib-resistant CLL cells expressed high-levels of MERTK and that, UNC-2025 synergistically induced apoptosis when combined with venetoclax. Thus, high MERTK-levels in CLL cells may be associated with ibrutinib-resistance underscoring the potential use of UNC-2025/venetoclax combination in treating relapsed/refractory patients.
- 23 September 2026
- Published by Springer Nature in Leukemia
- p. 1-17
Aberrant expression of MERTK activates BCR via CD79a in CLL cells: alternative therapeutic strategy for relapsed/refractory CLL
Although therapies targeting BTK of BCR-signal are changing the landscape of CLL management, these agents are not curative and resistance can develop. Thus, we searched for other druggable target(s) regulating leukemic B-cell survival for developing alternative therapies. We detected MERTK, a member of the TAM (Tyro3, AXL, MERTK) family receptor tyrosine kinases (RTKs), is aberrantly expressed and constitutively active in CLL cells from ~65% CLL patients (n = 100). Ligation of Gas6, a common ligand for TAM-RTKs, preferentially activated MERTK resulting in activation of NF-κB/AKT/Erk1/2 and BTK in CLL cells. Partial depletion of MERTK in CLL cells reduced P-Erk1/2, P-NF-κB, P-AKT, and P-BTK levels, suggesting that MERTK may crosstalk with BCR-signal. Indeed, MERTK activated BTK by forming a signalosome with CD79a/LYN in CLL cells. Interestingly, stimulation of BCR-signals in CLL cells activated MERTK via CD79a, suggesting that MERTK/BCR-signals are functionally connected. Importantly, targeting MERTK using a high-affinity, pharmacologic inhibitor UNC-2025 induced apoptosis in CLL cells and reduced leukemic burden in vivo. More significantly, ibrutinib-resistant CLL cells expressed high-levels of MERTK and that, UNC-2025 synergistically induced apoptosis when combined with venetoclax. Thus, high MERTK-levels in CLL cells may be associated with ibrutinib-resistance underscoring the potential use of UNC-2025/venetoclax combination in treating relapsed/refractory patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S3. List of Genes Regulated by Constitutively Active JAK2 in Steady-State CLL Cells.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S3. List of Genes Regulated by Constitutively Active JAK2 in Steady-State CLL Cells.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S5. Target genes of the AKT pathway.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S5. Target genes of the AKT pathway.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S2. Tyrosine phosphorylation status of JAK2.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S2. Tyrosine phosphorylation status of JAK2.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S8. Pathway Enrichment Analysis and Prediction.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S8. Pathway Enrichment Analysis and Prediction.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S1. CLL Patients’ Prognostic Characteristics.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S1. CLL Patients’ Prognostic Characteristics.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S7. JAK2-knockdown modulates transcript levels of specific gene-sets in CLL cells.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S7. JAK2-knockdown modulates transcript levels of specific gene-sets in CLL cells.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S4. Target genes of the Erk1/2 MAPK pathway.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Table S4. Target genes of the Erk1/2 MAPK pathway.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S3. HSP90 regulates AGK protein level in CLL cells.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S3. HSP90 regulates AGK protein level in CLL cells.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S4. Depletion of AGK reduces P-JAK2 level in CLL cells.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Supplementary Figure S4. Depletion of AGK reduces P-JAK2 level in CLL cells.